Autolus Therapeutics: Expanding Reach Of CD19 Therapy, But Far From Profitable (AUTL)

Autolus Therapeutics advances in CAR T-cell therapy with obe-cel, showing durable benefits. Click here to find out why AUTL stock is a Buy.